Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: Didanosine
  • Price: $300.0/100mg $600.0/250mg $1200.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao
Related CAS#:
69655-05-6 134892-26-5
124516-24-1 130676-58-3
142894-15-3 142894-17-5
117525-25-4 810694-79-2
130676-57-2 142504-05-0

69655-05-6

69655-05-6 structure
69655-05-6 structure
  • Name: 2',3'-Dideoxyinosine
  • Chemical Name: didanosine
  • CAS Number: 69655-05-6
  • Molecular Formula: C10H12N4O3
  • Molecular Weight: 236.227
  • Catalog: API Synthetic anti-infective drugs Antiviral drugs
  • Create Date: 2018-04-01 08:00:00
  • Modify Date: 2024-01-02 13:33:36
  • Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.Target: NRTIs; HIVDidanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy [2].
Name didanosine
Synonyms 9-[(2R,5S)-5-(hydroxyméthyl)tétrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
DDI
Videx
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydro-2-furanyl]-1,9-dihydro-6H-purin-6-one
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-9H-purin-6-ol
MFCD00077728
Inosine, 2’,3’-dideoxy-
VIDEX EC
2',3'-Dideoxyinosine
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
6H-Purin-6-one, 1,9-dihydro-9-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-
INOSINE, 2',3'-DIDEOXY-
Dideoxyinosine
Didanosine
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-on
didanosinum [INN_la]
Description Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.Target: NRTIs; HIVDidanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy [2].
Related Catalog
References

[1]. Knupp, C.A., et al., Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther, 1991. 49(5): p. 523-35.

[2]. Bissuel, F., et al., Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med, 1994. 235(4): p. 367-71.
Density 1.8±0.1 g/cm3
Boiling Point 531.2±60.0 °C at 760 mmHg
Melting Point 193-195 °C
Molecular Formula C10H12N4O3
Molecular Weight 236.227
Flash Point 275.0±32.9 °C
Exact Mass 236.090942
PSA 93.03000
LogP -1.31
Vapour Pressure 0.0±1.5 mmHg at 25°C
Index of Refraction 1.798
Storage condition 2-8°C
Stability Stable. Combustible. Incompatible with strong oxidizing agents.
Water Solubility 1-5 g/100 mL at 21 ºC

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NM7460700
CHEMICAL NAME :
Inosine, 2',3'-dideoxy-
CAS REGISTRY NUMBER :
69655-05-6
LAST UPDATED :
199803
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C10-H12-N4-O3
MOLECULAR WEIGHT :
236.26

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
2340 mg/kg/34W-I
TOXIC EFFECTS :
Liver - fatty liver degeneration Liver - jaundice, cholestatic Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
28 gm/kg/28D-I
TOXIC EFFECTS :
Immunological Including Allergic - decrease in humoral immune response

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
6 gm/kg/3D (Intermittent)
REFERENCE :
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 18,168,1991
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes C
Risk Phrases R34
Safety Phrases S26-S27-S36/37/39-S45
RIDADR NONH for all modes of transport
WGK Germany 2
RTECS NM7460700
HS Code 2942000000
HS Code 2942000000

Chemsrc provides CAS#:69655-05-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 69655-05-6 | Chemsrc address: https://m.chemsrc.com/en/baike/1192726.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved